<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are known to express BCL-2 family proteins, of which the myeloid cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>-1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1) protein is a member </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 is involved in viability and immortalization of <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic B cells, and expression is regulated transcriptionally and posttranscriptionally, resulting in an anti-apoptotic (full length) or a pro-apoptotic (short isoform) gene product </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we assessed 151 B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 expression and analyzed for expression of the full-length and short isoforms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 in B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>By using immunohistochemistry, a subset of <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in 9 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types studied expressed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1, but expression was more frequent and intense in high-grade (43 of 49, 88%) compared with low-grade (34 of 92, 37%) <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (P &lt; 0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>In follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 expression positively correlated with increasing grade; 1 (14%) of eight grade 1, 7 (70%) of ten grade 2, and <z:hpo ids='HP_0000001'>all</z:hpo> 9 (100%) grade 3 were positive (P &lt; 0.0008) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp> cases assessed were also <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 positive </plain></SENT>
<SENT sid="6" pm="."><plain>By using Western blot analysis, 6 of 7 high-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines showed predominant expression of full-length <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1, compared with no or weak expression of the short isoform </plain></SENT>
<SENT sid="7" pm="."><plain>One <z:mp ids='MP_0009440'>myeloma</z:mp> and 1 of 2 mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines also tested showed only full-length isoform expression </plain></SENT>
<SENT sid="8" pm="."><plain>Our data suggest that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 is frequently expressed in high-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp>, most likely in its full-length isoform that is an active anti-apoptotic gene product </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 expression also correlates with grade and may contribute to transformation in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>